GlassScriptPhysician profile
Christlieb E Gardiner
NPI 1891763942
$2,503.72
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,500 · 2022: $589 · 2023: $283 · 2024: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $407.48 | 2021-2023 | Mounjaro, Trulicity |
| Novo Nordisk INC | $284.37 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $245.07 | 2021-2024 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $206.30 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $171.08 | 2021 | |
| Abbvie INC. | $171.01 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $163.29 | 2021-2023 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.79 | 2021-2022 | |
| Eisai INC. | $88.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $79.04 | 2022 | |
| Esperion Therapeutics, INC. | $63.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.37 | 2021-2022 | |
| Csl Behring | $57.01 | 2021-2022 | |
| Mylan Specialty L.P. | $51.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.25 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $43.09 | 2021 | |
| Pfizer INC. | $40.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $37.48 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $32.91 | 2021 | |
| Amarin Pharma, INC. | $31.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.39 | 2021-2022 | |
| Genentech USA, INC. | $28.86 | 2021 | |
| Apria Healthcare LLC | $23.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.63 | 2021 | |
| Merck Sharp & Dohme LLC | $14.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christlieb Gardiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.